For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Neorx Corporation

USPTO Granted Patents = 156

% Expired Patents = 8.3

CIPO Patents = 1

Forward Citations = 6,549

Loading Chart...

Loading Chart...

69 inventors (with patents filed for the assignee):

Alan R Fritzberg (44 out of 53 patents)

Sudhakar Kasina (38 out of 50 patents)

John M Reno (36 out of 45 patents)

4. Ananthachari Srinivasan (33 out of 48 patents)

5. David John Grainger (20 out of 42 patents)

6. Linda M Gustavson (20 out of 32 patents)

7. James C Metcalfe (18 out of 20 patents)

8. Louis J Theodore (17 out of 23 patents)

9. Paul G Abrams (15 out of 19 patents)

10. Lawrence L Kunz (15 out of 17 patents)

11. Donald B Axworthy (13 out of 15 patents)

12. Daniel S Wilbur (13 out of 13 patents)

13. Peter L Weissberg (12 out of 13 patents)

14. Mark D Hylarides (9 out of 12 patents)

15. A Charles Morgan, Jr (9 out of 15 patents)

Core Competencies:

Radiolabeled Annexins

Radionuclide Complexes

Targeting Protein-Diagnostic Conjugates

Therapeutic Inhibitors

Pretargeting Methods

Cardiovascular Pathologies

Biotin-DOTA Conjugates

Aromatic Amine Ligands

Hepatic-Directed Compounds

Nitro-Benzyl-DOTA

Small Molecular Weight Ligands

Chelating Compounds

156 patents: Sort by Forward Citations

1. 7115720 - Therapeutic and diagnostic compounds, compositions, and methods (2006-10-03),

2. 7115248 - Radiolabeled annexins (2006-10-03),

3. 7097823 - High dose radionuclide complexes for bone marrow suppression (2006-08-29),

4. 7094885 - Skeletal-targeted radiation to treat bone-associated pathologies (2006-08-22),

5. 7094550 - Method to determine TGF-beta (2006-08-22),

6. 7084171 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2006-08-01),

7. 7070759 - High dose radionuclide complexes for bone marrow suppression (2006-07-04),

8. 6936700 - Bridged aromatic substituted amine ligands with donor atoms (2005-08-30),

9. 6767531 - High dose radionuclide complexes for bone marrow suppression (2004-07-27),

10. 6734208 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2004-05-11),

11. 6709652 - Pretargeting methods and compounds (2004-03-23),

12. 6663881 - Therapeutic inhibitor of vascular smooth muscle cells (2003-12-16),

13. 6599928 - Therapeutic inhibitor of vascular smooth muscle cells (2003-07-29),

14. 6569441 - Therapeutic inhibitor of vascular smooth muscle cells (2003-05-27),

15. 6534037 - Non-steroidal compounds for steroid receptors and uses relating thereto (2003-03-18),

Neorx Corporation, based in Seattle, WA, specializes in the development of radiolabeled therapeutics aimed at addressing various medical conditions, particularly in the realm of cardiovascular pathologies. The company focuses on innovative technologies such as radiolabeled annexins and radionuclide complexes, which facilitate targeted therapy and diagnostics. Their expertise extends to creating protein-diagnostic conjugates and therapeutic inhibitors, utilizing advanced pretreatment methods and biotin-DOTA conjugates to enhance treatment efficacy.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Neorx Corporation

156 Patents

#15 in Seattle, WA

#50 in Washington

#2,539 in US

#5,250 in the World

Seattle, WA, United States of America

Neorx Corporation

Forward Citations = 6,549

69 inventors:

Alan R Fritzberg (44 out of 53 patents)

Sudhakar Kasina (38 out of 50 patents)

John M Reno (36 out of 45 patents)

4. Ananthachari Srinivasan (33 out of 48 patents)

5. David John Grainger (20 out of 42 patents)

Please report any incorrect information to [email protected]

Loading…